Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telmisartan + S-amlodipine is a fixed-dose combination of two antihypertensive agents used to treat high blood pressure (hypertension). Telmisartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the type 1 angiotensin II receptor in vascular smooth muscle and the adrenal gland, leading to vasodilation and reduced aldosterone secretion. S-Amlodipine is the S-enantiomer of amlodipine, a calcium channel blocker (CCB), which inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels. The combination provides better blood pressure control than either agent alone by targeting different mechanisms involved in hypertension[1][2][5]. This therapy reduces cardiovascular risk associated with uncontrolled hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telmisartan + s-amlodipine.